

## Adverse Drug Reaction Collection Form

Fill out mandatory items (\*) and complete form with additional information, if possible.

Send filled form to Drug Safety Allergopharma:

E-Mail: pharmacovigilance@allergopharma.com

You will find this documentation at: www.allergopharma.com

Allergopharma GmbH & Co. KG Drug Safety Hermann-Körner-Str. 52 21465 Reinbek • Germany

Phone inquiries: +49 40 72765712

1. Reporter Details							
Name (*):		Phone (*):			Reporter is:	0 - 1	
		Fax:			<ul><li>O Physician</li><li>O Pharmacis</li></ul>	O Relative	
		E-Mail:			O Patient	O other:	
2. Patient Details					O ratient	O other.	
2. I diletti Details							
Initials:		Date of birth: DD.MM.YYYY			Hight: (cm)		
Sex (*): O male O female O unknown		Age: (years)			Weight: (kg)		
7 Cuanastad Draduct D	ataila		,,,		vveigitt.	(N9)	
3. Suspected Product D	etalis	The		£.	Thermon		!-!
Product name (*): Allergen composition:		The reaction was observed at a dose of:			Therapy start last administratio		ministration
9			trength: (1,2,3 or	A,B)	DD.MM.YYYY	DD.MM	.YYYY
Batch No:		Standard dose escalation     Accelerated dose escalation			Indication:		
		O One-strength dose escalation			Route of administration:		
Parallel Allergen Immunothera	apy? O yes	O no	Product name	e:			
Date of last administration:		_	Allergen com	position:			
	DD.MM.YYYY		Batch No:				
Actions taken on the suspect  O Drug discontinued	ted drug:  O Dose uncha	angod	O Dose changed:	ml / -t		O unkno	uun.
-		inged	O Dose changed	1111 / Str	ength:	O UTIKITO	VVII
4. Adverse Drug React							
<b>Diagnosis (*)</b> (if unknown	Start DD.MM.YYYY	End DD.MM.YYYY	Onset after administration	Durati	on	Outcome (A)	Causality (B)
signs and symptoms)							
(A) Choose: 1 = recovered/resolv							nknown
(B) Choose: 1 = certain, 2 = prob	able, 3 = possible	, 4 = unlikely, 5 =	unassessable/unclassifie	ed, 6 = not r	elated, 7 = unkr	nown	
Description of reaction::							

Fax: +49 40 72765252



## Adverse Drug Reaction Collection Form

5. Treatment of Adv	verse Drug Reac	tion						
Drug			Dosage	Dosage		Route of administration		
O none O unknown			J					
O Antihistamine								
O Steroid								
O β-Sympathomimetics								
O Adrenaline/Epinephrin	e							
O Others, e.g. local treatr	ment							
Did reaction reappear after reintroduction?  O yes O no O unknown			Did reaction abate after use stopped or dose reduced?  O yes O no O unknown					
6. Seriousness of Re	eaction							
O non-serious O serious, please specify: O Death O Life-threatening O Hospitalization prolonged O Permanent or serious disability O Hospitalization O Congenital anomaly / birth defect O Other medically important condition								
7. Medical History								
O none O unknown				Start date DD.MM.YYYY	End date ′ DD.MM.YYY	Ongoing Y		
Asthma O yes	O no O unknown					O yes O no		
Other diseases:						O yes O no		
						O yes O no		
						O yes O no		
8. Concomitant Dru	ıg Therapy							
O none O unknown	.9							
Drug I	Product name	Dosage	Route of administration		End date DD.MM.YYYY	Indication		
9. Has this case bee	en reported?							
O no O yes, please	specify:							
O directly to Allergopharma O to Allergopharma External sales O Competent Authority O others:								
				Stamp	or address:	_		

CC/OC TIMI OLD OCCOUNTS

2/2

Signature of reporter: \_

(Physician/pharmacist)

DD.MM.YYYY